All In Biotech

Drug Trial Radar · NCT05909397

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer

A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF VEPDEGESTRANT (ARV-471/PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)

Last checked: Nov 19, 2026Latest source record: Feb 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

59

Actual

Start

Aug 9, 2023

Primary completion

Dec 30, 2026

Study completion Dec 30, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
Collaborators
Arvinas Estrogen Receptor, Inc.
First posted
Jun 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to understand the safety and effects of the study medicine vepdegestrant (ARV-471/PF-07850327) given together with palbociclib in advanced breast cancer. In particular, the study will compare the combination of vepdegestrant plus palbociclib to standard of care therapy (letrozole plus palbociclib). Both letrozole and palbociclib are medicines already used for treatment of breast cancer. Vepdegestrant is a new medicine under study. This study is seeking participants who have breast cancer that: * Have a locally advanced or metastatic disease and cannot be fully cured by surgery or radiation therapy. A metastatic disease is when disease has spread to other parts of the body. * Is sensitive to hormonal therapy such as tamoxifen. This is called estrogen receptor positive disease. * Have not received any prior medicine for advanced disease. Example medications include tamoxifen or letrozole or exemestane. The study will have an open-label SLI (study lead-in) before initiation of Phase 3 trial. During SLI, two dose levels of palbociclib in combination with vepdegestrant will be explored in parallel. Assignment to the palbociclib dose is by chance. Half of the participant will receive one dose and the other half another palbociclib dose. The purpose of SLI is to determine the recommended Phase 3 dose of palbociclib to be administered in combination with vepdegestrant. In the Phase 3, half of the participants will take vepdegestrant plus palbociclib while the other half will take letrozole plus palbociclib. In both SLI and Phase 3, participants will take the study medicines by mouth, with food, once a day. Participants will take the study medicines until breast cancer increase in size or side effects become too severe. Side effects refer to unwanted reactions to medications. Participants will visit the study clinic about once every 4 weeks.

Conditions

  • Breast Cancer

Interventions

  • Vepdegestrant (ARV-471/PF-07850327)Drug

    Pharmaceutical form: Tablets. Route of Administration: Oral

  • PalbociclibCombination product

    Pharmaceutical form: Capsules. Route of Administration: Oral.

  • LetrozoleDrug

    Pharmaceutical form: Capsules. Route of Administration: Orally

  • PalbociclibCombination product

    Pharmaceutical form: Capsules. Route of Administration: Oral.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Study Lead-in (SLI): Incidence of Grade 4 neutropeniaTime frame: From randomization date up to Cycle 4 (each cycle is 28 days).
  2. SLI: Incidence of dose reductionTime frame: From randomization date up to Cycle 4 (each cycle is 28 days).
  3. SLI: Incidence of drug discontinuation.Time frame: From randomization date up to Cycle 4 (each cycle is 28 days).
  4. Phase 3: Progression-Free SurvivalTime frame: From randomization date, every 12 weeks, to date of first documentation of progression or death, up to approximately 4 years.

Locations

29 sites in 10 countries. Site status is shown where the registry gives one.

  • BRCR Global

    Plantation, Florida

  • BRCR Medical Center Inc

    Plantation, Florida

  • Virginia Oncology Associates

    Norfolk, Virginia

  • Cancer Research SA

    Adelaide, South Australia, Australia

  • Barwon Health

    Geelong, Victoria, Australia

  • Hospital Santa Rita de Cassia

    Vitória, Espírito Santo, Brazil

  • Centro Gaucho Integrado De Oncologia, Hematologia, Ensino E Pesquisa

    Porto Alegre, Rio Grande do Sul, Brazil

  • Centro de Pesquisa Clínica - Área Administrativa

    Porto Alegre, Rio Grande do Sul, Brazil

  • Hospital Mae de Deus

    Porto Alegre, Rio Grande do Sul, Brazil

  • Cancer Hospital Chinese Academy of Medical Science

    Beijing, Beijing Municipality, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Hubei Cancer Hospital

    Wuhan, Hubei, China

  • The First Affiliated Hospital of Xi'an Jiaotong University

    Xi'an, Shaanxi, China

  • Debreceni Egyetem Klinikai Kozpont

    Debrecen, Hungary

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale

    Naples, Campania, Italy

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"

    Meldola, Emilia-Romagna, Italy

  • Fondazione IRCCS San Gerardo dei Tintori

    Monza, Lombardy, Italy

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, Japan

  • National Cancer Center Hospital

    Chuo-ku, Tokyo, Japan

  • Nemocnica na okraji mesta n o

    Partizánske, Slovakia

  • Fakultna nemocnica s poliklinikou J.A. Reimana Presov

    Prešov, Slovakia

  • Hospital Unviersitario Virgen Nieves

    Granada, Spain

  • Hospital Clinico San Carlos

    Madrid, Spain

  • Institut Català d'Oncologia (ICO) - Badalona

    Badalona, Barcelona [barcelona], Spain

  • Hospital Universitari Dexeus

    Barcelona, Catalunya [cataluña], Spain

  • Complejo Hospitalario de Jaén

    Jaén, JAÉN, Spain

  • Hospital Universitario Virgen de la Victoria

    Málaga, Málaga, Spain

  • Tumor Zentrum Aarau

    Aarau, Canton of Aargau, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.